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Abstract 
Background: The World Health Organization guidelines have recommended that all cases of suspected malaria 
should receive a confirmatory test with microscopy or a malaria rapid diagnostic test (RDT), however evidence from 
sub-Saharan Africa (SSA) illustrates that only one-third of children under five with a recent fever received a test. The 
aim of this study was to evaluate availability, price and market share of microscopy and RDT from 2009/11 to 2014/15 
in 8 SSA countries, to better understand barriers to improving access to malaria confirmatory testing in the public and 
private health sectors.
Results: Repeated national cross-sectional quantitative surveys were conducted among a sample of outlets stock-
ing anti-malarial medicines and/or diagnostics. In total, 169,655 outlets were screened. Availability of malaria blood 
testing among all screened public health facilities increased significantly between the first survey wave in 2009/11 
and the most recent in 2014/15 in Benin (36.2, 85.4%, p < 0.001), Kenya (53.8, 93.0%, p < 0.001), mainland Tanzania 
(46.9, 89.9%, p < 0.001), Nigeria (28.5, 86.2%, p < 0.001), Katanga, the Democratic Republic of the Congo (DRC) (76.0, 
88.2%, p < 0.05), and Uganda (38.9, 95.6%, p < 0.001). These findings were attributed to an increase in availability of 
RDTs. Diagnostic availability remained high in Kinshasa (the DRC) (87.6, 97.6%) and Zambia (87.9, 91.6%). Testing avail-
ability in public health facilities significantly decreased in Madagascar (88.1, 73.1%, p < 0.01). In the most recent survey 
round, the majority of malaria testing was performed in the public sector in Zambia (90.9%), Benin (90.3%), Madagas-
car (84.5%), Katanga (74.3%), mainland Tanzania (73.5%), Uganda (71.8%), Nigeria (68.4%), Kenya (53.2%) and Kinshasa 
(51.9%). In the anti-malarial stocking private sector, significant increases in availability of diagnostic tests among 
private for-profit facilities were observed between the first and final survey rounds in Kinshasa (82.1, 94.0%, p < 0.05), 
Nigeria (37.0, 66.0%, p < 0.05), Kenya (52.8, 74.3%, p < 0.001), mainland Tanzania (66.8, 93.5%, p < 0.01), Uganda (47.1, 
70.1%, p < 0.001), and Madagascar (14.5, 45.0%, p < 0.01). Blood testing availability remained low over time among 
anti-malarial stocking private health facilities in Benin (33.1, 20.7%), and high over time in Zambia (94.4, 87.5%), with 
evidence of falls in availability in Katanga (72.7, 55.6%, p < 0.05). Availability among anti-malarial stocking pharmacies 
and drug stores—which are the most common source of anti-malarial medicines—was rare in all settings, and high-
est in Uganda in 2015 (21.5%). Median private sector price of RDT for a child was equal to the price of pre-packaged 
quality-assured artemisinin-based combination therapy (QAACT) treatment for a two-year old child in some countries, 
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Background
Since 2010, the World Health Organization (WHO) 
guidelines have recommended that all cases of suspected 
malaria should receive a confirmatory test with micros-
copy or a rapid diagnostic test (RDT) to confirm the 
diagnosis [1] and since 2012, this recommendation has 
been promoted through WHO’s ‘test, treat, and track’ 
strategy. Although malaria remains a public health con-
cern, resulting in over 300,000 deaths in children under 
five [1], recent control efforts have significantly reduced 
the disease burden, especially in high transmission areas 
of Africa [2]. The decreased prevalence of malaria has 
emphasized the need to move away from presumptive 
treatment. This, together with the introduction of RDT 
technology, has allowed for malaria diagnosis to take 
place in remote and resource-poor settings [3], and has 
influenced the shift in policy to confirmatory testing [4].
Confirmatory testing of suspected cases of malaria with 
microscopy or RDT prior to treatment has the potential 
to enhance accurate diagnosis, and improve treatment 
of malaria and other febrile illnesses and reduce wastage 
of anti-malarial drugs [5]. Confirmatory testing has been 
shown to decrease the inappropriate use of the effective 
artemisinin-based combination therapy (ACT), which is 
the first-line treatment for the majority of countries in 
sub-Saharan Africa (SSA) [1]. It is thought that reducing 
inappropriate use of this treatment will impede the rate 
of resistance to ACT and decrease how much govern-
ments will need to spend on purchasing and supplying 
these medicines to health facilities [6–9].
National guidelines across SSA stipulate confirmatory 
testing prior to treatment, and national malaria control 
programmes and their partners have implemented strate-
gies to improve access to testing through the scale up of 
RDT, particularly in the public sector [10]. Despite this, 
current evidence from population-based surveys sug-
gests that confirmatory testing rates with microscopy or 
RDT remain low. According to recent household surveys 
conducted between 2013 and 2015 in SSA, the propor-
tion of children under five with recent fever who received 
a malaria test was just 31% (Interquartile range [IQR] 
19–40%) [1].
Current and comprehensive information about avail-
ability, price and the relative sale or distribution of RDT 
versus microscopy in the public and private sectors for 
diagnostic testing in SSA is needed. This will help to 
inform and monitor strategies to increase the proportion 
of suspected malaria cases receiving a confirmatory test. 
However, this information has to date not been avail-
able. Most studies that evaluate accessibility to malaria 
diagnostic testing tend to be small in scale, not nation-
ally representative, focus on either the public or private 
sector only, or observe only one time point [11–15]. A 
more recent multi-country ACTwatch assessment of 
malaria diagnostic testing availability across the pub-
lic and private sectors, published in 2015, focused solely 
on RDT availability in eight SSA countries during 2011 
[16]. Other data on availability, price and market share of 
microscopy and RDT have been made available through 
multiple survey rounds, but data have not yet been col-
lated across countries and presented overtime for key 
indicators.
ACTwatch was launched in 2008 by Population Ser-
vices International (PSI), with support from the Bill 
and Melinda Gates Foundation, UNITAID and the UK 
Department for International Development (DFID) 
and was implemented in collaboration with the London 
School of Hygiene and Tropical Medicine. The goal of the 
project was to generate timely, relevant, and high quality 
evidence about anti-malarial markets for policy makers, 
donors, and implementing organizations. The aim of this 
paper is to address gaps in information concerning pub-
lic and private sector availability, price and market share 
of microscopy and RDTs across eight malaria-endemic 
countries in SSA (Benin, the Democratic Republic of the 
Congo [DRC], Nigeria, Kenya, mainland Tanzania (sub-
sequently referred to as Tanzania), Uganda, Madagascar 
and Zambia). Data collected by the ACTwatch project 
over multiple time points between 2009/11 and 2014/15 
are presented to describe significant trends in availability, 
and 1.5–2.5 times higher in others. Median private sector QAACT price for an adult varied from having parity with an 
RDT for an adult to being up to 2 times more expensive. The exception was in both Kinshasa and Katanga, where the 
median price of QAACT was less expensive than RDTs.
Conclusions: Significant strides have been made in the availability of testing, mainly through the widespread distri-
bution of RDT, and especially in public health facilities. Significant barriers to universal coverage of diagnostic testing 
can be attributed to very low availability in the private sector, particularly among pharmacies and drug stores, which 
are responsible for most anti-malarial distribution. Where tests are available, price may serve as a barrier to uptake, 
particularly for young children. Several initiatives that have introduced RDT into the private sector can be modified 
and expanded as a means to close this gap in malaria testing availability and promote universal diagnosis.
Keywords: Malaria test, Rapid diagnostic test, Microscopy, Price, Market share, Availability, sub-Saharan Africa
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and to summarize private sector price and relative mar-
ket share of RDT and microscopy for the public and 
private sector. Policy regarding private sector permis-
sion to use RDT varies by country and outlet type (see 
Table  1) and data are also presented to describe differ-
ences between private sector outlet types. The results will 
be useful to inform, monitor, and evaluate policies and 
strategies designed to improve access and use of malaria 
diagnostic testing.
Methods
Design and sampling
ACTwatch outlet surveys are nationally-representative 
(with the exception of the sub-national surveys in the 
DRC), cross-sectional quantitative surveys conducted 
among a sample of outlets stocking anti-malarial medi-
cines and diagnostics. Detailed ACTwatch project and 
methodological information have been published else-
where [17, 18].
All categories of outlets with the potential to stock 
anti-malarials in both the public and private sector were 
included in the study. Potential outlets include public and 
private outlets that may be likely to stock anti-malarial 
medicines or diagnostics according to each country con-
text. In the public sector, this included government and 
non-government not-for-profit health facilities (hospi-
tals, health centres, clinics, and health posts) and com-
munity health workers. Outlets sampled in the private 
sector included private for-profit health facilities (hospi-
tals, health centres, and clinics), pharmacies, drug stores 
(registered/regulated and unregistered/unregulated), 
general retailers selling fast-moving consumer goods and 
itinerant drug vendors (mobile vendors without a fixed 
service delivery point).
Lists of all potentially eligible outlets were not routinely 
available and therefore a cluster sampling approach with 
an outlet census was used to identify outlets for inclusion. 
Clusters were administrative units ideally with a size of 
10,000–15,000 inhabitants, and were selected using prob-
ability proportional to population size sampling. Within 
each selected cluster all outlets with the potential to pro-
vide anti-malarials to consumers were screened for eligi-
bility. Outlets were eligible for an anti-malarial product 
audit if they had one or more anti-malarials in stock on 
the day of the survey or/and malaria diagnostic testing.
Boundaries for the outlet census were typically 
extended to higher administrative units to cover a larger 
area for the census of public health facilities and pharma-
cies, in order to over-sample these relatively uncommon 
but important outlet types.
Each survey was stratified to deliver estimates for rele-
vant research domains: all countries had urban and rural 
stratification, with the exception of Nigeria for which 
six geopolitical zones were used as research domains. 
Each study round was powered to detect a minimum of 
a 20-percentage point change in availability of quality-
assured ACT (QAACT) among anti-malarial stock-
ing outlets between each round and between domains 
in a given round at the 5% significance level with 80% 
power. The number of study clusters was calculated for 
each research domain based on the required number of 
anti-malarial stocking outlets and assumptions about 
Table 1 National policy regarding permission to administer RDT across private sector outlet types
Private for-profit health facilities Pharmacies and drug stores
West and Central Africa
 Benin Only accredited private health facilities are permitted to administer testing
 DRC Permitted to administer RDT Pharmacies with a licensed pharmacist are permitted to administer RDT. Other drug 
stores are not allowed to administer RDT
 Nigeria Permitted to administer RDT Drug stores, or Patient Propriety Medicines Vendors (PPMV) as they are called in Nigeria, 
were granted approval to administer RDT in 2015 at national level. Approval at sub-
national level varies across states. Pharmacies are allowed to administer RDT within 
approved project pilots as of 2014
East Africa
 Kenya Permitted to administer RDT Not permitted to administer RDT. Pharmacies are allowed to administer RDT within 
approved project pilots as of 2014
 Tanzania Permitted to administer RDT Accredited drug dispensing outlets (ADDOs) are allowed to administer RDT within 
approved project pilots. Policy granting permission to administer RDT for ADDOs is 
under review
 Uganda Permitted to administer RDT Drug stores and pharmacies are allowed to administer RDT within approved project 
pilots. Policy granting permission to administer RDT is under review
Southern Africa
 Madagascar Permitted to administer RDT Pharmacies and drug stores permitted to administer RDT nationwide since 2014
 Zambia Permitted to administer RDT Not permitted to administer RDT
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the number of anti-malarial stocking outlets per cluster. 
Sample size requirements for follow-up surveys were cal-
culated using information from previous survey rounds 
including anti-malarial and QAACT availability, outlet 
density per cluster, and design effect.
Data collection periods varied by country and over time 
but were typically implemented during the peak malaria 
transmission season for each country and lasted between 
6 weeks and 2 months. Efforts were made to ensure sur-
veys were implemented over similar time points across 
the survey rounds.
Training and fieldwork
Interviewer training consisted of standardized class-
room presentations and exercises as well as a field exer-
cise. Exams administered during training were used to 
select data collectors, supervisors, and quality-control-
lers. Additional training was provided for supervisors 
and quality-controllers and focused on field monitoring, 
verification visits, and census procedures. Data collection 
teams were provided with a list of selected clusters and 
official maps that illustrated their administrative bounda-
ries. In each selected cluster, data collectors conducted a 
full enumeration of all outlets that had the potential to 
provide anti-malarials and/or malaria blood testing. This 
included enumeration of outlets with a physical location, 
as well as identification of community health workers and 
itinerant drug vendors using local informants and snow-
ball sampling. The primary provider/owner of each out-
let was invited to participate in the study, and screening 
questions were administered to assess anti-malarial or/
and malaria diagnostic availability. Interviews were con-
ducted in local language using questionnaires that were 
translated from English to the local language using a for-
wards and backwards blind translation. Quality control 
measures implemented during data collection included 
questionnaire review by supervisors, and spot checks by 
quality controllers on 10–20% of all outlets.
Measures
The outlet survey questionnaire included an audit of all 
available RDT. Providers were asked to show the inter-
viewer all RDT that were available in the outlet. A prod-
uct audit sheet captured information for each unique 
RDT in the outlet, including brand name, manufacturer, 
and country of manufacture. Providers were asked to 
report the retail and wholesale price for each RDT as 
well as the number of RDT distributed/administered to 
individual customers in the previous week. Providers 
additionally reported on malaria microscopy services 
including availability, price, and number of individuals 
tested for malaria by microscopy in the previous week 
(see Additional file  1 for a sample of the ACTwatch 
questionnaire). All surveys were paper-based with the 
exception of Madagascar (2015) and Uganda (2015), 
where data were collected using Android phones and 
forms created using DroidDB (© SYWARE, Inc., Cam-
bridge, MA, USA).
Protection of human subjects
The outlet survey protocols received ethical approval 
from national ethical approval boards within each coun-
try. Provider interviews and product audits were com-
pleted only after administration of a standard informed 
consent form and provider consent to participate in 
the study. Providers had the option to end the inter-
view at any point during the study. Standard measures 
were employed to maintain provider confidentiality and 
anonymity.
Data analysis
Double data entry was conducted using Microsoft Access 
(Microsoft Corporation, Redmond, WA, USA) with built-
in range and consistency checks. Data were analyzed 
across survey rounds using Stata (StataCorp College Sta-
tion, TX).
Standard indicators were constructed according to def-
initions applied across the ACTwatch project which have 
been described elsewhere [17, 18]. Availability of RDT 
was defined as presence of one or more RDT at the out-
let at the time of the survey. Availability of microscopy 
was defined as provider report of availability of malaria 
microscopy testing services. Functionality of the micro-
scope and availability of slides and Giemsa stain were 
not confirmed. Availability of malaria testing was calcu-
lated among all screened outlets for public health facili-
ties, and among anti-malarial stockists for all other outlet 
types. An anti-malarial stockist was defined as an outlet 
with one or more anti-malarials in stock on the day of the 
survey, or reportedly in stock within the past 3 months. 
Significant differences in test availability levels between 
years in each country were estimated using logistic 
regression, with a binary dependent variable for availabil-
ity of testing at the outlet level, and a dummy independ-
ent variable for year.
The private sector price of a malaria test using micros-
copy or RDT was assessed through provider reports of 
consumer prices for the last survey round. Price data pre-
sented were collected in local currencies and converted 
to United States dollars using official exchange rates for 
the period of data collection. Providers were asked to 
report the total cost of testing to a customer including 
any consultation or service fees. Median private sector 
price for RDTs was calculated and reported with the IQR 
as a measure of dispersion. Median estimates were not 
reported on in cases of low sample size, specifically where 
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the N contributing to a median price estimate was below 
20. Price of testing was compared with median price 
for pre-packaged treatment with a first-line QAACT. 
In countries with two first-line ACT, the most common 
was selected for the median price comparison. The most 
common pre-packaged QAACT treatment for an adult 
was artemether-lumefantrine (AL) in all countries except 
Madagascar and Kinshasa (DRC) and Katanga (DRC) 
where it was artesunate–amodiaquine (ASAQ). The 
price of testing for an adult was compared to the price 
of pre-packaged therapy for a 60 kg adult (e.g. AL 20/120 
package size of 24 tablets). The price of testing for a child 
under five was compared to the price of pre-packaged 
therapy for a 10 kg child (e.g. AL 20/120 package size of 
6 tablets).
QAACT were ACT products meeting one of three 
criteria: (1) the product had WHO pre-qualified status; 
(2) the product was in compliance with the Global Fund 
quality assurance policy and appeared on the Global 
Fund list of approved products for procurement; or (3) 
the product was granted regulatory approval by the Euro-
pean Medicines Agency.
Provider reports on the number of people tested using 
RDT or malaria microscopy during the week preced-
ing the survey were used to calculate the relative market 
share for the public and private sector and for the type 
of test (RDT and microscopy). The relative market share 
for a sector or test type is the number of tests that were 
reportedly performed on each customer during the week 
preceding the survey for the sector/test type as a percent-
age of all tests performed across sectors.
Outlets were grouped into three main categories: (1) 
public health facilities consisting of government and pri-
vate not-for-profit facilities; (2) private for-profit health 
facilities; and (3) pharmacies and drug stores. Results are 
presented separately for private for-profit health facili-
ties and pharmacies/drug stores given the differences in 
testing policy for these outlet types (Table 1). Additional 
file  2 includes findings for other outlet types including 
community health workers, general retailers, and itin-
erant drug vendors, given the general low availability of 
malaria blood testing among these outlet types.
Sampling weights were calculated as the inverse of the 
probability of cluster selection. All point estimates were 
weighted using survey settings and all standard errors 
calculated taking account of the clustered and stratified 
sampling strategy with Stata survey commands.
Results
A total of 198,836 outlets were screened to assess avail-
ability of anti-malarials and blood testing across the 
eight countries and 28 survey rounds between 2009/11 
and 2014/15. Anti-malarials were available on the day 
of the survey or within the previous 3 months among a 
total of 52,312 outlets. In total, 11,981 RDT were audited 
(Table 2).
Malaria blood testing availability
The availability of malaria blood testing (RDT or 
microscopy) among all screened public health facilities 
increased significantly between 2009/11 and 2014/15 
in Benin (36.2, 85.4%, p  <  0.001), Kenya (53.8, 93.0%, 
Table 2 Results of  the outlet census and  RDT audit 
by country and survey year
n/a not applicable, indicates years during which RDT availability was assessed 
but an audit of all available RDT was not conducted
a Outlets with at least one anti-malarial in stock on the day of the survey or 
within the past 3 months (completed interview)
b Represents the number of RDT products that were audited at an outlet during 
each survey round
Country Year Screened (N 
of outlets)
Anti-malarial 
 stockista (N 
of outlets)
RDT products 
 auditedb (N 
of products)
West and Central Africa
 Benin 2011 2891 1413 96
2014 4332 1939 239
 Kinshasa 
(DRC)
2009 2368 777 n/a
2013 3364 977 79
2015 1168 1078 267
 Katanga 
(DRC)
2013 2270 785 140
2015 1052 1027 435
 Nigeria 2009 5456 2160 n/a
2011 7938 1548 44
2013 5148 1784 448
2015 13,480 3568 489
East Africa
 Kenya 2010 13,897 2554 75
2011 11,383 2084 144
2014 12,676 2405 654
 Tanzania 2010 3120 650 28
2011 3702 798 41
2014 4724 2138 504
 Uganda 2010 11,153 2499 180
2011 16,207 3226 843
2013 7932 3472 1573
2015 9438 4598 2267
Southern Africa
 Madagascar 2010 6769 2593 n/a
2011 10,046 2790 722
2013 10,149 1906 1087
2015  13,481 1203 699
 Zambia 2009 3378 459 n/a
2011 5436 860 278
2014 5878 1021 649
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p  <  0.001), Tanzania (46.9, 89.9%, p  <  0.001), Nigeria 
(28.5, 86.2%, p < 0.001), Katanga (76.0, 88.2%, p < 0.05), 
and Uganda (38.9, 95.6%, p < 0.001). Testing availability 
was not significantly different between survey rounds in 
Kinshasa (87.6, 97.6%) and Zambia (87.9, 91.6%). Testing 
availability significantly decreased in Madagascar (88.1, 
73.1%, p < 0.01) (Fig. 1).
A significant increase in availability of RDT was found 
in Benin (30.5, 75.4%, p  <  0.001), Kenya (8.7, 62.6%, 
p  <  0.001), Tanzania (20.8, 76.2%, p  <  0.001), Kinshasa 
(2.9, 50.4%, p < 0.001), Katanga (47.8, 84.7%, p < 0.001), 
Nigeria (8.6, 83.4%, p  <  0.001), and Uganda (4.0, 83.6%, 
p  <  0.001) (Table  3). In Madagascar there was a signifi-
cant decline in testing availability of RDT (Table 3).
In the anti-malarial stocking private sector, the avail-
ability of malaria blood testing (RDT or microscopy) 
among the private for-profit sector increased signifi-
cantly between 2009/11 and 2014/15 in Kinshasa (82.1, 
94.0%, p  <  0.05), Nigeria (37.0, 66.0%, p  <  0.05), Kenya 
(52.8, 74.3%, p < 0.001), Tanzania (66.8, 93.5%, p < 0.01), 
Uganda (47.1, 70.1%, p  <  0.001) and Madagascar (14.5, 
45.0%, p < 0.01). Blood testing availability did not change 
significantly over time in Benin (33.1, 20.7%). and Zam-
bia (94.4, 87.5%). Significant declines were observed in 
Katanga (72.7, 55.6%, p < 0.05) (Fig. 2).
In comparison with private for-profit facilities, the 
availability of malaria blood testing among anti-malarial 
stocking pharmacies and drug stores was lower across 
all countries. During the most recent survey round, test-
ing availability among anti-malarial stocking pharmacies 
and drug stores ranged from 0.1% in Benin to 21.5% in 
Uganda. Among pharmacies and drug stores, a significant 
increase in availability was observed between 2009/11 
and 2014/15 in Nigeria (1.1, 7.1%, p < 0.001), Kenya (10.7, 
17.0%, p < 0.05), Tanzania (0.4, 6.2%, p < 0.001), Uganda 
(4.5, 21.5%, p  <  0.001), and Madagascar (0.4, 12.4%, 
p < 0.001) (Fig. 2).
Among private for-profit facilities, a significant 
increase in availability of RDT was observed in Nige-
ria (11.0, 42.4%, p < 0.05), Kenya (6.7, 29.3% p < 0.001), 
Uganda (9.7, 47.7%, p  <  0.001), and Madagascar (12.5, 
43.8%, p  <  0.01). In Kenya, significant increases in 
microscopy availability were observed (48.5, 61.1%, 
p  <  0.05). In Katanga, malaria microscopy availabil-
ity showed significant declines (49.2, 23.3%, p  <  0.01) 
(Table  4). Among pharmacies and drugs stores, a sig-
nificant increase in availability of RDT was observed in 
Nigeria (0.5, 7.0%, p < 0.05), Kenya (2.2, 12.8% p < 0.001), 
Tanzania (0.4, 5.7%, p  <  0.01), Uganda (2.2, 20.7%, 
p  <  0.001), and Madagascar (0.45, 12.4%, p  <  0.001) 
Notes: Tests for significance differences in malaria testing availability between first and final years of the survey rounds 
Benin DRC, 
Kinshasa
DRC, 
Katanga
Nigeria Kenya Tanzania Uganda Madagascar Zambia
*** ns * *** *** *** *** ** ns
Abbreviations: ns: Not significant;      * p<0.05;     ** p<0.01;      *** p<0.001
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Fig. 1 Availability of malaria blood testing among all screened public health facilities (Public health facilities are inclusive of government and non-
government not-for-profit hospitals, clinics, health centers and health posts), 2009/11–2014/15
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(Table 4). Microscopy was rarely available among phar-
macies and drug stores in all countries with the excep-
tion of Kenya (6.1% in 2014) (Table 4).
In some study countries, community health work-
ers, general retailers, and itinerant drug vendors stock-
ing anti-malarials were also stocking RDT. Among 
anti-malarial stocking community health workers, RDT 
availability was 58.2% during the most recent survey 
round in Uganda, 72.8% in Madagascar and 83.2% in 
Zambia. Availability among general retailers and itiner-
ant drug vendors was generally very low (<5%) with the 
exception of 8.5% observed during the most recent sur-
vey in Tanzania (Additional file 2).
Private sector price of malaria blood testing relative 
to treatment
The median private sector price of the most common 
pre-packaged QAACT treatment for an adult was 2 times 
more expensive than the median price of adult RDT test-
ing in Tanzania, Uganda, and Zambia, and 1.25 more 
expensive in Nigeria. QAACT and RDT testing were the 
same price in Kenya and Madagascar. In both Kinshasa 
and Katanga, the median price of QAACT ($0.00 and 
$0.55, respective) was less expensive than RDT testing 
(both $1.10). The low price of adult QAACT in Kinshasa 
is attributed to low availability of products (N = 40), 
which were part of small scale subsidy initiatives. 
Malaria microscopy was more expensive than QAACT 
for adults in Benin (1.9 times more expensive), Katanga 
(2 times more expensive), and Kinshasa (where median 
price of treatment was $0.00), Nigeria (1.2 times more 
expensive), and Madagascar (8.3 times more expensive), 
and was the same price as treatment in Kenya. QAACT 
was more expensive than microscopy in Tanzania (2 
times more expensive) and Uganda (1.7 times more 
expensive) (Fig. 3).
The median private sector price of RDT testing for a 
child was higher than the price of pre-packaged QAACT 
treatment for a 2-year old child in Katanga (2.5 times 
more expensive), Nigeria (1.4 times more expensive), 
Kenya (2 times more expensive), Uganda (2.1 times more 
expensive), and Zambia (1.5 times more expensive). The 
prices of treatment and of RDT for a child were the same 
in both Tanzania and Madagascar. Malaria microscopy 
for a child was also more expensive than pre-packaged 
pediatric treatment in Benin (4.9 times more expen-
sive), Katanga (3.3 times more expensive), Nigeria (4.2 
times more expensive), Kenya (2 times more expensive), 
Uganda (2.1 times more expensive), and Madagascar 
(8.3 times more expensive). The prices of QAACT and of 
Table 3 Percentage of all screened public health  facilitiesa 
with RDT and microscopy available on the day of the sur-
vey, over time
a Inclusive of government and non-government not-for-profit hospitals, clinics, 
health centers and health posts
CI Confidence Interval
* p < 0.05; ** p < 0.01; *** p < 0.001, in reference to baseline year
n % Outlets stocking 
RDT (95% CI)
% Outlets 
with microscopy 
available (95% CI)
West and Central Africa
 Benin
  2011 257 30.5 (21.3, 41.7) 8.8 (5.0, 15.1)
  2014 263 75.4 (64.6, 83.8)*** 17.8 (11.4, 26.8)*
 Kinshasa (DRC)
  2009 27 2.9 (0.5, 14.2) 86.2 (66.1, 95.3)
  2013 89 23.5 (13.3, 38.1) 89.3 (81.0, 94.3)
  2015 277 50.4 (39.9, 61.0)*** 91.2 (84.5, 95.1)
 Katanga (DRC)
  2013 97 47.8 (34.0, 61.9) 47.6 (36.3, 59.1)
  2015 284 84.7 (77.2, 90.0)*** 30.8 (24.2, 38,2)*
 Nigeria
  2009 249 8.6 (1.8, 32.9) 28.5 (10.7, 56.9)
  2011 109 14.9 (7.5, 27.7) 24.7 (14.8, 38.4)
  2013 711 43.0 (29.6, 57.6) 12.6 (5.8, 25.4)
  2015 210 83.4 (72.7, 91.0)*** 27.8 (15.9, 44.2)***
East Africa
 Kenya
  2010 443 8.7 (4.6, 16.0) 49.8 (43.2, 56.4)
  2011 474 18.5 (9.7, 32.4) 44.6 (36.1, 53.5)
  2014 528 62.6 (55.6, 69.0)*** 66.4 (62.2, 70.4)***
 Tanzania
  2010 87 20.8 (10.1, 38.0) 28.1 (20.0, 38.0)
  2011 64 38.6 (23.5, 56.3) 25.0 (15.4, 37.8)
  2014 336 76.2 (69.4, 81.9)*** 32.3 (26.2, 39.0)
 Uganda
  2010 811 4.0 (1.7, 9.2) 36.2 (28.8, 44.3)
  2011 718 51.2 (44.7, 57.6) 47.8 (41.5, 54.2)
  2013 728 79.5 (71.8, 85.5) 41.4 (36.1, 47.0)
  2015 334 83.6 (75.4, 89.5)*** 59.0 (51.1, 66.6)***
Southern Africa
 Madagascar
  2010 524 87.4 (81.3, 91.6) 3.7 (2.1, 6.3)
  2011 669 89.7 (84.9, 93.1) 5.7 (4.6, 7.2)
  2013 620 87.4 (82.7, 91.0) 14.7 (7.7, 26.2)
  2015 273 72.0 (62.0, 80.3)** 3.6 (2.3, 5.5)
 Zambia
  2009 178 85.7 (70.4, 93.8) 40.6 (30.5, 51.6)
  2011 294 68.4 (55.4, 79.0) 35.8 (24.9, 48.5)
  2014 498 89.4 (83.8, 93.2) 22.8 (14.3, 34.3)*
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microscopy for a child were the same in Tanzania (Fig. 4). 
In Kinshasa, the median price of prepackaged QAACT 
for a 2-year-old child was $0.00, meaning that median 
price for both RDT and microscopy was higher than for 
treatment here. The low price of QAACT for a 2-year-
old child in Kinshasa is attributed to low availability of 
products (N = 13), which were part of small scale subsidy 
initiatives.
Private sector prices for quality-assured pre-packaged 
ACT treatment and testing disaggregated by outlet type 
(private facility, pharmacy/drug store) are provided in 
Additional file 3.
Malaria blood testing market share
At the time of the most recent survey round, the major-
ity of malaria testing was performed in the public sector 
in Zambia (90.9%), Benin (90.3%), Madagascar (84.5%), 
Tanzania (73.5%), Uganda (71.8%), Nigeria (68.4%), 
Kenya (53.2%), and the DRC, where the public sector was 
responsible for 74.3% of tests performed in Katanga and 
51.9% in Kinshasa. The majority of malaria blood test-
ing was performed with RDT in Zambia (89.9%), Benin 
(76.5%), Madagascar (96.5%), Tanzania (63.5%), Uganda 
(70.8%), Nigeria (78.7%), and Katanga (81.9%). Micros-
copy performed by both the public and private sectors 
accounted for the majority of malaria testing in Kenya 
(75.4% inclusive of 37.3% public and 38.1% private) and 
Kinshasa (63.7% inclusive of 26.9% public and 36.8% pri-
vate) (Fig. 5).
Discussion
The results from this study show that significant strides 
have been made in improving availability of malaria test-
ing, especially in public health facilities, where more than 
80% of facilities stocked any test across most countries 
during the last survey round. However, population based 
evidence suggests that testing uptake remains low, with 
only about one-third of children under five with recent 
fever receiving a malaria test [19]. The findings from 
this survey suggest that this may be attributed to a lack 
of private sector availability of testing and price barriers, 
particularly in pharmacies and drugs stores, where most 
patients seek treatment in SSA.
Limitations
The main strength of this paper is that data are presented 
at a national level, with the exception of the DRC where 
only Katanga and Kinshasa provinces were surveyed par-
tially due to poor infrastructure that limited travel, and 
to insecurity in other regions of the country. In addition, 
this study assessed availability, price, and market share in 
both the public and private sector, providing a complete 
picture of the malaria testing market. However, several 
limitations exist. Information on pricing was obtained 
Notes: Test for significance difference in testing availability in the private sector (total) between first and final survey rounds 
Benin DRC, 
Kinshasa
DRC, 
Katanga
Nigeria Kenya Tanzania Uganda Madagascar Zambia
Private for-profit facilities ns *** * * *** ** *** ** ns
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Abbreviations: ns: Not significant; * p<0.05 ** p<0.01;; *** p<0.001
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Fig. 2 Availability of malaria blood testing among the anti-malarial stocking private sector, 2009/11–2014/15
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by asking the provider how much they would charge 
for a test, which may have exposed the data to respond-
ent bias as providers may state a price they consider 
more favorable to the interviewers. Another limitation 
is that the quality of the RDT or functionality of micro-
scopic tests stocked was not assessed, nor was expiry 
Table 4 Percentage of  anti-malarial-stocking private sector outlets with  malaria RDT and  microscopy available on  the 
day of the survey over time
a Private for-profit health facilities (hospitals, clinics and health centres) and pharmacies or drug stores with anti-malarials in stock on the day of the survey or within 
the previous 3 months
* p < 0.05 ** p < 0.01 *** p < 0.001, in reference to baseline year
Private for-profit health  facilitiesa Pharmacies and drug stores
N % Outlets stocking  
RDT (95% CI)
% Outlets with  
microscopy (95% CI)
N % Outlets stocking  
RDT (95% CI)
% Outlets with  
microscopy (95% CI)
West and Central Africa
 Benin
  2011 134 11.2 (2.4, 38.9) 22.5 (14.4, 33.4) 221 2.2 (9.8, 5.1) 0.0
  2014 139 11.6 (5.2, 23.8) 10.5 (4.0, 24.6) 192 0.1 (< 0.1, 0.4)*** 0.1 (< 0.1, 0.4)
 Kinshasa (DRC)
  2009 71 5.1 (1.9, 13.0) 81.5 (72.0, 88.2) 661 0.1 (0.0, 1.0) 0.9 (0.4, 2.0)
  2013 200 18.3 (13.2, 25.0) 89.3 (84.2, 92.8) 693 0.4 (0.1, 2.3) 0.0
  2015 176 31.1 (21.8, 42.2) 88.7 (83.2 92.5) 612 1.3 (0.5, 3.2) 0.1 (< 0.1, 1.9)
 Katanga (DRC)
  2013 134 45.4 (33.4, 58.0) 49.2 (35.2, 63.3) 529 5.4 (3.7, 7.7) 2.2 (1.0, 4.8)
  2015 141 45.9 (36.5, 55.5) 23.3 (15.6, 33,4)** 565 9.4 (5.9, 14.6) 0.8 (0.4, 1.8)
 Nigeria
  2009 367 11.0 (2.7, 36.0) 36.1 (29.4, 43.4) 1360 0.5 (0.1, 1.9) 0.6 (0.2, 1.8)
  2011 93 8.6 (3.3, 20.6) 33.2 (19.5, 50.4) 1206 0.9 (0.3, 2.6) 0.2 (< 0.1, 0.9)
  2013 78 46.9 (30.3, 64.2) 24.0 (12.0, 42.2) 885 6.9 (4.3, 11.0) 0.2 (0.1, 1.1)
  2015 240 42.4 (29.3, 56.7)* 41.9 (18.3, 70.0) 2956 7.0 (5.2, 9.4) *** <0.1 (< 0.1, 0.3)*
East Africa
 Kenya
  2010 269 6.7 (3.2, 13.6) 48.5 (37.7, 59.4) 655 2.2 (0.8, 6.0) 8.8 (5.8, 13.0)
  2011 280 6.7 (3.7, 11.8) 40.2 (30.4, 50.8) 744 3.1 (1.8, 5.2) 7.6 (5.1, 11.2)
  2014 375 29.3 (25.7, 33.0)*** 61.1 (56.7, 65.4)* 1045 12.8 (11.0, 14.9)** 6.1 (4.8, 7.8)
 Tanzania
  2010 10 8.8 (1.0, 49.1) 58.0 (27.0, 83.8) 455 0.4 (0.1, 1.5) <0.1 (< 0.1, 0.2)
  2011 25 3.4 (0.6, 17.8) 61.4 (31.6, 84.6) 673 1.0 (0.3, 3.3) 1.4 (0.7, 3.1)
  2014 172 47.7 (40.1, 55.5) 83.1 (75.6, 88.6) 1599 5.7 (3.9, 8.1)*** 0.7 (0.3, 1.8)**
 Uganda
  2010 394 9.7 (6.6, 14.0) 41.3 (36.3, 46.6) 1220 2.2 (1.2, 3.8) 2.6 (1.2, 4.8)
  2011 811 20.3 (15.7, 25.8) 43.5 (39.2, 47.8) 1544 5.1 (3.6, 7.2) 2.5 (1.4, 4.6)
  2013 394 31.4 (25.9, 37.4) 46.6 (37.6, 55.8) 1512 11.2 (8.4, 14.8) 2.4 (1.4, 4.1)
  2015 966 47.7 (41.7, 53.8)*** 41.1 (34.3, 48.1) 2381 20.7 (17.8, 23.9)*** 1.1 (0.6, 2.3)
Southern Africa
 Madagascar
  2010 71 12.5 (6.5, 22.9) 4.3 (2.1, 8.5) 324 0.4 (0.1, 1.1) 0.1 (< 0.1, 0.3)
  2011 47 7.7 (3.5, 15.9) 3.6 (1.5, 8.4) 461 2.4 (1.2, 4.6) 0.0
  2013 94 45.9 (32.9, 59.5) 9.7 (4.4, 20.4) 529 1.7 (1.0, 3.0) 0.7 (0.1, 5.0)
  2015 182 43.8 (28.0, 60.9)** 3.1 (1.6, 5.7) 271 12.4 (6.5, 22.3)*** 0.0
 Zambia
  2009 33 78.3 (58.0, 90.5) 74.4 (57.8, 86.1) 189 4.2 (0.9, 17.1) 3.1 (0.4, 20.2)
  2011 49 43.8 (23.6, 66.2) 86.9 (73.1, 94.2) 362 12.7 (4.3, 32.2) 0.1 (< 0.1, 0.6)
  2014 22 68.1 (45.6, 84.4) 72.2 (42.0, 90.3) 354 14.3 (6.5, 28.7) 0.4 (0.1, 0.9)
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Fig. 3 Median private sector price for malaria testing for an adult and quality-assured adult ACT treatment
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Fig. 4 Median private sector price for malaria testing for a child and quality-assured pediatric ACT treatment
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information on stocked RDT collected. In addition, while 
tests may have been available at an outlet, the length of 
waiting time for the results was not assessed, though one 
would expect this to be longer for microscopy than for 
RDTs. Other limitations specific to the ACTwatch meth-
odology are described in more detail elsewhere [20].
Public health facilities
Increases in testing availability were observed among 
public health facilities in several countries. At least nine 
in ten public sector facilities had malaria testing avail-
able in Kinshasa (DRC), Kenya, Tanzania, Uganda, and 
Zambia, and availability was greater than 85% in Benin 
and Katanga (DRC). Large increases in availability over 
time were observed across most countries, and this was 
most striking in Benin and Tanzania between the last two 
survey rounds, where availability increased by almost 
fifty percentage points. Statistically significant differ-
ences were found between the first and final surveys for 
all country contexts, with the exception of Kinshasa and 
Zambia. These increases were largely achieved through 
the extensive deployment of RDT. Market share data, 
presented for the last survey round, also illustrated that 
the majority of confirmatory tests (up to 90%) were being 
carried out in public health facilities, exemplifying the 
importance of this sector as a source of confirmatory 
testing. In addition, across country contexts, the most 
common type of test carried out in public health facili-
ties was RDT, with some exceptions noted in Kenya and 
Kinshasa where microscopy was more commonly admin-
istered and available.
These findings reflect policies of confirmatory diagno-
sis that many African countries have adopted since WHO 
changed its malaria treatment policy to ‘test, treat, and 
track.’ Several countries have implemented programmes 
aimed at expanding access to and use of diagnostic testing 
among public health facilities, largely focusing on RDT 
given evidence that these can be effectively performed 
even at lower levels of the health system [21]. The find-
ings presented here are commensurate with public sector 
surveillance data from the region, indicating that the pro-
portion of suspected malaria cases receiving a confirma-
tory test in the public sector increased from 40% in 2010 
to 76% in 2015 [1]. Again this is attributed to an increase 
in the use of RDT, which accounted for 74% of diagnostic 
testing among suspected cases in 2015 [1]. This trend of 
increased confirmatory testing among public health facil-
ities is also evident in the results of household surveys, 
where the proportion of febrile children who received a 
malaria diagnostic test in the public sector rose from a 
median of 29% in 2010 (IQR: 19–46%) to a median of 51% 
in 2015 (IQR: 35–60%) [1]. Similarly, distribution of RDT 
from national malaria control programmes in SSA to 
supply the public sector has also increased over the years, 
and a total of 179 million were distributed to the public 
sector in 2015 [1].
Despite these improvements over time among public 
health facilities, the findings from the last survey round 
demonstrate that gaps persist and 100% coverage of con-
firmatory diagnosis has not yet been achieved. In Mada-
gascar, only three-quarters of public health facilities had 
testing available, reflecting a decline in recent years and 
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a significant reduction since the baseline survey. Stock-
outs are known to be a common problem facing the pub-
lic health sector, and this has been demonstrated with 
inconsistent supplies of ACT [22]. In Madagascar, the 
reduction in availability of RDT among public health 
facilities may be explained by a delay in funding, with 
orders of RDTs only arriving in country in July 2015 after 
several months of stock-outs. Indeed, several challenges 
have been reported with maintaining constant public 
sector supply including the lack of technical capacity, 
archaic procurement methods, and cumbersome tender-
ing processes [23]. Investments to strengthen both the 
supply system and the health information system, using 
systems such as the District Health Information Software 
(DHIS2), will assist in tracking RDT availability and lend 
to a more streamlined, demand driven, and accountable 
procurement and supply chain system [24].
Private sector
In contrast to the public sector, there has been very lit-
tle progress in testing scale up in the anti-malarial stock-
ing private sector, particularly among pharmacies and 
drug stores—which are the most common source of 
anti-malarial medicines [18]. The percentage of outlets 
stocking any test in pharmacies and drug stores remained 
negligible across most country contexts, and was high-
est in Uganda in 2015 where 21% of pharmacies/drugs 
stores had a test in stock. Availability in the private sec-
tor was somewhat higher among private for-profit facili-
ties, where modest improvements in the percentage of 
outlets stocking any test were observed, driven by a rise 
in RDT distribution. The findings from the outlet sur-
vey mirror evidence from population-based surveys in 
SSA that illustrate how the proportion of febrile chil-
dren who received a malaria diagnostic test was greater if 
they sought care in the public sector (median: 51%, IQR: 
35–60%) than in the formal private sector (median: 40%, 
IQR: 28–57%) or in the informal private sector (median: 
9%, IQR: 4–12%) [1].
The low availability of malaria tests in pharmacies and 
drug stores is a key barrier to improving universal access 
to confirmatory testing since these outlet types are an 
important source of malaria treatment. For example, in 
Nigeria, over 70% of anti-malarial medicines were dis-
tributed through drug stores [25], known as PPMVs, yet 
less than 10% of these outlets had malaria testing avail-
able. Similarly in Tanzania, almost half of the total mar-
ket share was distributed by pharmacies and drug stores 
(ADDOs), but only 6% had confirmatory testing available 
[26].
Low private sector availability of malaria testing can 
partly be explained by national regulatory frameworks, 
which restrict testing in these outlet types. However, 
there is a growing body of evidence that malaria case 
management can be well administered among certain 
outlet types in the private sector. In Tanzania, a ran-
domized controlled trial to investigate whether the 
introduction of RDT among ADDOs improved malaria 
case management found that confirmatory diagnosis 
increased from 19 to 74% in intervention districts, which 
also resulted in improved targeting of ACT to patients 
with malaria [12]. Similar positive outcomes have been 
demonstrated among Licensed Chemical sellers in 
Ghana (private retail sector shops) [27] and drug shops in 
Uganda [28]. As such, several strategies have been piloted 
in SSA countries to facilitate access to confirmatory test-
ing within pharmacies and drug stores. It has been shown 
that these outlets can safely and correctly test for malaria 
with appropriate training, supervision, and record keep-
ing [29]. This suggests that the policy in favor of confirm-
atory testing in pharmacies and drug stores may foster 
increased access and appropriate case management of 
suspected malaria cases.
However, scaling up malaria testing within the private 
sector is not without challenges. While national scale 
implementation of RDT in the private sector has not 
yet been observed in SSA, this has been implemented in 
Cambodia over the past 10 years. A review of Cambodia’s 
private sector strategy has pointed to several challenges 
in maintaining constant supply of RDT and determining 
effective incentives for private providers and patients to 
use RDTs and adhere to results [30]. Furthermore, scale-
up of RDTs in the private sector is not without major 
logistical challenges to ensure appropriate provision and 
supply of these commodities and at the same time guar-
antee safe blood practices and appropriate disposal of 
RDT. There may also be inadvertent effects on the use 
of antibiotics. Studies from Zanzibar [31] and mainland 
Tanzania [32] have shown increased prescription rates 
for antibiotics when RDTs were introduced, particu-
larly for negative cases. Scale-up of RDTs in the private 
sector would also require time and substantial financial 
resources, which some may argue could be better spent 
on supervising the public sector. Careful consideration of 
future private sector strategies is needed and approaches 
should be reviewed according to each country’s context 
and regulatory framework.
Prices were only assessed for the last survey round, and 
only in the private sector, since tests within the public 
sector should be free. In the private sector, the median 
private sector price of pre-packaged QAACT treatment 
for an adult was either the same price or up to two times 
more expensive than the median price of an RDT, with 
the exception of Kinshasa and Katanga where the median 
price of treatment was less expensive than RDT test-
ing. In contrast, the median private sector price of RDT 
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testing for a child was higher than or equal to the price 
of pre-packaged QAACT treatment for a 2-year old child 
across countries. The median microscopy prices were 
generally higher than the price of carrying out an RDT in 
both adults and children.
These findings illustrate that where testing is avail-
able in the private sector, there appears to be a financial 
incentive in many cases for adults to test before treat-
ment. However, among children, the low cost of pre-
packaged ACT relative to RDT means that there is less 
of a financial incentive to test before purchasing ACT for 
this age group.
It has been suggested that in order to improve uptake 
of testing and therefore targeted treatment, the cost of 
testing should be lower than the cost of ACT [9, 33]. 
One possible way of achieving this is to subsidize RDT 
in the private sector along with ACT. Previous empirical 
research has provided some support for a combined sub-
sidy. For example, a study in Uganda showed that intro-
ducing subsidized RDT in drug shops, alongside training 
and community awareness programmes, was able to sig-
nificantly improve appropriate treatment of malaria over 
time. RDT-positive patients were 23 percentage points 
more likely to buy ACT (p = .005) and 33.1 percentage 
points more likely to buy other antimalarials (p < .001) 
than RDT-negative patients[9]. Lessons learned from 
pilot studies have shown that such subsidies do increase 
uptake of RDT [33, 34], and are most effective when 
prices are at a level that will still create sufficient profit 
to encourage providers to offer testing as a service, and 
manufacturers to continue producing these products [9, 
34, 35]. RDT subsidies will need to be supported with 
behavior change communication to safeguard the proper 
use of the tests by providers [34, 35] and to ensure febrile 
patients are encouraged to test prior to treatment.
Achieving high levels of confirmatory testing prior to 
treatment and ensuring rational ACT use will require 
solutions that include the private sector. As previously 
discussed, this may include the introduction of subsi-
dized RDT into certain outlet types in the private sector 
such as drug stores that play a role in malaria case man-
agement. Indeed, several studies have provided evidence 
that acceptance of malaria testing is generally high, with 
most patients welcoming the idea of receiving treatment 
based on a confirmed diagnosis [36–38]. However, recent 
evidence has pointed to several challenges around the 
poor communication practices between providers and 
patients, and the testing process, including limited inter-
personal exchange between providers and patients which 
can lead to poor malaria case management [39]. To 
overcome this, future strategies may benefit from clear 
provider protocols to enable a more effective patient 
assessment and discussion on test outcomes, to include 
reasons for carrying out the test, particularly among 
RDT-negative patients [38]. There are also inherent chal-
lenges when patients test negative for malaria, particu-
larly in the private sector, where providers may not have 
the qualifications or experience to know how to correctly 
manage the patient [30]. There is also evidence that pro-
viders do not always comply with testing guidelines and 
may treat patients with anti-malarials despite negative 
malaria tests for several reasons, including a mistrust in 
the accuracy of the tests [5, 6]. Provider strategies to over-
come these challenges could include testing guidelines, as 
well as continuous training and monitoring [27, 29, 40] 
and the use of SMS messaging to improve both use of 
tests and compliance to test guidelines [41]. In addition, 
parallel efforts could be implemented such as incentive 
schemes, including bundling free ACT medicines with 
provider wholesale purchases of subsidized tests, to help 
promote provider uptake, distribution and increase profit 
margins [34, 42]. Such strategies and approaches may be 
adapted and refined according to each country’s context 
and regulatory framework(s).
Conclusion
The results from this paper have shown that significant 
strides have been made in the availability of testing, espe-
cially in public health facilities, most notably due to an 
increase in the procurement of RDT. In the public sector, 
universal coverage of confirmatory diagnosis has almost 
been achieved in many countries and most confirma-
tory malaria tests are administered through this sector. 
However, stock-outs and procurement challenges must 
be continually monitored to ensure constant supply and 
uptake of RDT. In contrast, persistent gaps still remain 
in the private sector, with availability lagging behind the 
public sector, especially among pharmacies and drug 
stores, where most anti-malarials are distributed. This 
may be attributed to national regulations prohibiting the 
provision of malaria testing in these outlets, but also to 
RDT price barriers, particularly for children, which serve 
as a disincentive to test prior to treatment. These issues 
have the potential to impact both malaria control efforts 
and prospects for elimination, however several private 
sector strategies may provide innovative solutions for 
maximizing testing services across a range of contexts.
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